Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13722420 | 0.88 | MAP4K4 (0.38) | HCRTR1HCRTR2MAP4K4POLBLMNA | |
| SCHEMBL13721980 | 0.86 | MAP4K4 (0.35) | MAP4K4POLBLMNAGAATSHR | |
| SCHEMBL2600248 | 0.82 | MAP4K4 (0.45) | MAP4K4POLBLMNAGAATSHR | |
| SCHEMBL13522014 | 0.82 | HCRTR1 (0.40) | HCRTR1HCRTR2MAP4K4POLBLMNA | |
| SCHEMBL18977639 | 0.77 | POLB (0.42) | HCRTR1HCRTR2POLBLMNAGAA | |
| SCHEMBL19193199 | 0.77 | POLB (0.44) | HCRTR1HCRTR2POLBLMNAGAA | |
| SCHEMBL10177642 | 0.76 | POLB (0.46) | HCRTR1HCRTR2POLBLMNAGAA | |
| SCHEMBL13522003 | 0.76 | RAB9A (0.35) | POLBLMNAGAATSHRHTT | |
| SCHEMBL10120678 | 0.74 | POLB (0.47) | HCRTR1HCRTR2POLBLMNAGAA | |
| SCHEMBL2600225 | 0.70 | MAP4K4 (0.45) | MAP4K4TSHRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004284-A1 | Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004284-A1 | Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM1, GRIK5 | HCRTR1 136/4885HCRTR2 167/4885MAP4K4 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.